Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib with modified FOLFOX6 in advanced biliary cancers
NCT01229111Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in biliary tract cancer (BTC), sponsored by National Cancer Institute. Started Oct 2010; status: terminated.
02
Drugs
cediranib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01229111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01229111.